babesiose (Babesia species)
Advices
Priority | Medication | Remarks |
---|---|---|
Medication: clindamycine iv 600mg 3dd 10 days +
quinine po 650mg 3dd 10 days |
Remarks:
B. divergens/venatorum of ernstige B. microti |
|
Medication: clindamycine po 600mg 3dd 10 days +
quinine po 650mg 3dd 10 days |
Remarks:
Alternatief bij B. divergens/venatorum of ernstige B. microti |
|
Medication: atovaquon po 750mg 2dd 7 to 10 days +
azitromycine po loading dose 500mg, 250mg 1dd 7 to 10 days |
Remarks:
niet ernstige B. microti |
Sources
-
Pubmed.gov publication # 22716978
Vannier E, Krause PJ (2012) Human babesiosis. N Engl J Med. 366(25):2397-407
-
Pubmed.gov publication # 25999229
Vannier EG, et al. Infect Dis Clin North Am. 2015; 29(2):357-370
-
Pubmed.gov publication # 31622632
Odedra A, Lalloo DG, Kennedy G, Llewellyn S, McCarthy JS (2019) Safety and effectiveness of apheresis in the treatment of infectious diseases: A systematic review. J Infect. 79:513-520.
-
Pubmed.gov publication # 34578196
Hildebrandt, A. et al. (2021) Human Babesiosis in Europe. Pathogens 10(9):1165.
Antimicrobial resources
The following antimicrobial agents have been used in these recommendations:
External antimicrobial resources
Menu position
Metadata
Swab vid: G-147702.4
Updated: 12/29/2023 - 12:13
Status: Published
General comments